BOSTON, Oct. 17 /PRNewswire/ -- TEI Biosciences Inc. announces the launch of its SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction product. TEI has received 510(k) clearance from the U.S. Food and Drug Administration to market SurgiMend for expanded use in plastic and reconstructive surgery, including breast reconstruction, and for tendon augmentation, in addition to the previously cleared hernia repair and muscle flap reinforcement indications.
“SurgiMend has been the biologic material of choice for many general, plastic, and trauma surgeons for their hernia repair and muscle flap reinforcement needs. With multiple indications, excellent handling and suturing characteristics, and a rapid hydration rate that saves valuable operating room time, SurgiMend has the potential to become the medical community’s primary choice for soft tissue repair and reconstruction. In addition, SurgiMend provides an opportunity for hospitals to cover a broad range of applications with a single biologic device at a single price point,” said Yiannis Monovoukas, Ph.D., TEI’s Chairman, President, and CEO.
SurgiMend is an acellular, terminally sterilized biologic matrix derived from the dermis of fetal calves, one of the purest sources of collagen available. It is intrinsically strong yet soft and pliable when hydrated, and handles like natural tissue; it readily conforms to the surgical site and is easily sutured. SurgiMend is rich in Type III collagen, the active collagen found in developing and healing tissues. It is not artificially crosslinked and its biochemistry and microporosity facilitate rapid cell penetration, revascularization, and integration with host tissues. SurgiMend is available in multiple sizes, both large and small, and can be stored dry at room temperature for up to three years.
SurgiMend will be on display at the American Society of Plastic Surgeons meeting in Baltimore, MD, October 29-30, at booth # 145.
About TEI Biosciences
A Boston-based, privately-held, leading biomedical company, TEI Biosciences Inc. (www.teibio.com) has applied its expertise in regenerative medicine to develop and commercialize novel biologic products for a broad spectrum of soft tissue repair and reinforcement applications -- from dura, tendon, and hernia repair to wound management and plastic and reconstructive surgery.
TEI sells its products directly and through partnerships with some of the world’s major medical device companies. In addition to SurgiMend, TEI’s marketed products include:
ymonovoukas@teibio.comtony.russo@russopartnersllc.com
CONTACT: Yiannis Monovoukas, Ph.D., of TEI Biosciences Inc.
ymonovoukas@teibio.com, or Tony Russo, Ph.D., of Russo Partners, LLC for
TEI Biosciences Inc., +1-212-845-4251, tony.russo@russopartnersllc.com
Web site: http://www.teibio.com/
